{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:06:39Z","timestamp":1781885199539,"version":"3.54.5"},"reference-count":98,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcf.2026.03.023","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T20:44:14Z","timestamp":1776113054000},"page":"443-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Maldigestion, dysbiosis, inflammation and dysmotility: a toxic tetrad in the CF gut"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3290-7355","authenticated-orcid":false,"given":"Rosara","family":"Bass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.03.023_bib0001","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/17476348.2023.2228194","article-title":"Thinking outside the box: a review of gastrointestinal symptoms and complications in cystic fibrosis","volume":"17","author":"Yule","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jcf.2026.03.023_bib0002","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcf.2016.02.002","article-title":"International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: associated factors and outcome","volume":"15","author":"Munck","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0003","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ccm.2015.11.004","article-title":"Gastrointestinal disorders in cystic Fibrosis","volume":"37","author":"Assis","year":"2016","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jcf.2026.03.023_bib0004","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jcf.2022.10.006","article-title":"Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis","volume":"22","author":"Moshiree","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0005","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1177\/2050640619841545","article-title":"A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders","volume":"7","author":"Hayee","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.jcf.2026.03.023_bib0006","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/thoraxjnl-2017-210473","article-title":"The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers","volume":"73","author":"Rowbotham","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2026.03.023_bib0007","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/thorax-2023-220100","article-title":"A refresh of the top 10 research priorities in cystic fibrosis","volume":"78","author":"Rowbotham","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2026.03.023_bib0008","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcf.2019.06.005","article-title":"Do current clinical trials in cystic fibrosis match the priorities of patients and clinicans? A systematic review","volume":"19","author":"Kalaitzis","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0009","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009753","article-title":"The cystic fibrosis intestine","volume":"3","author":"De Lisle","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2026.03.023_bib0010","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jcf.2017.07.014","article-title":"Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the Cystic Fibrosis intestine","volume":"16","author":"Dorsey","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0011","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s10620-012-2209-1","article-title":"Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule","volume":"58","author":"Gelfond","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jcf.2026.03.023_bib0012","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/MPG.0b013e318290d112","article-title":"Delayed small bowel transit in children with cystic fibrosis and pancreatic insufficiency","volume":"57","author":"Rovner","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2026.03.023_bib0013","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV-functional GI Disorders: disorders of gut-brain interaction","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcf.2026.03.023_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71214","article-title":"Disorders of gut-brain interaction in a pediatric cystic fibrosis cohort","volume":"60","author":"Smith","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0015","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/ueg2.12617","article-title":"Symptom profiles compatible with disorders of gut-brain interaction (DGBI) in organic gastrointestinal diseases: a global population-based study","volume":"12","author":"van Gils","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.jcf.2026.03.023_bib0016","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.pmn.2017.11.011","article-title":"Descriptions of the pain experience in adults and adolescents with Cystic fibrosis","volume":"19","author":"Allgood","year":"2018","journal-title":"Pain Manag Nurs"},{"key":"10.1016\/j.jcf.2026.03.023_bib0017","article-title":"Global burden of anxiety and depression among cystic fibrosis patient: systematic review and meta-analysis","volume":"2021","author":"Guta","year":"2021","journal-title":"Int J Chronic Dis"},{"key":"10.1016\/j.jcf.2026.03.023_bib0018","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12890-021-01473-y","article-title":"Insomnia in adults with cystic fibrosis: strong association with anxiety\/depression and impaired quality of life","volume":"21","author":"Mulette","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jcf.2026.03.023_bib0019","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/thoraxjnl-2017-210858","article-title":"Gaps in the evidence for treatment decisions in cystic fibrosis: a systematic review","volume":"74","author":"Rowbotham","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2026.03.023_bib0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1085\/jgp.200810122","article-title":"CFTR functions as a bicarbonate channel in pancreatic duct cells","volume":"133","author":"Ishiguro","year":"2009","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0021","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1084\/jem.20120562","article-title":"Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype","volume":"209","author":"Gustafsson","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcf.2026.03.023_bib0022","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.3748\/wjg.v16.i24.2978","article-title":"Small intestinal bacterial overgrowth syndrome","volume":"16","author":"Bures","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0023","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0016-5085(00)70358-1","article-title":"Identification of transport abnormalities in duodenal mucosa and duodenal enterocytes from patients with cystic fibrosis","volume":"118","author":"Pratha","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcf.2026.03.023_bib0024","series-title":"UK cf registry. annual data report 2024","year":"2025"},{"key":"10.1016\/j.jcf.2026.03.023_bib0025","series-title":"Cystic fibrosis foundation patient registry: 2024 annual data report","year":"2025"},{"key":"10.1016\/j.jcf.2026.03.023_bib0026","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/ppul.26257","article-title":"Need to study simplification of gastrointestinal medication regimen in cystic fibrosis in the era of highly effective modulators","volume":"58","author":"Sathe","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0027","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2012.12.011","article-title":"Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis","volume":"11","author":"Lo","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0028","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MPG.0000000000003459","article-title":"Changes in glucose breath test in cystic fibrosis patients treated with 1 month of lumacaftor\/ivacaftor","volume":"75","author":"Gabel","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2026.03.023_bib0029","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jcf.2020.06.004","article-title":"Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by magnetic resonance imaging","volume":"20","author":"Ng","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0030","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jcf.2021.12.007","article-title":"Magnetic resonance imaging of the gastrointestinal tract shows reduced small bowel motility and altered chyme in cystic fibrosis compared to controls","volume":"21","author":"Dellschaft","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0032","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jcf.2021.11.014","article-title":"Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis","volume":"21","author":"Marsh","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0033","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jcf.2024.08.001","article-title":"A longitudinal study assessing the impact of elexacaftor\/tezacaftor\/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI)","volume":"23","author":"Yule","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0034","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/MPG.0b013e3181a6e01d","article-title":"Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS","volume":"50","author":"Houwen","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2026.03.023_bib95","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S1569-1993(11)60005-2","article-title":"Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients","volume":"10","author":"Colombo","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/tgh-23-59","article-title":"The current state of gastrointestinal motility evaluation in cystic fibrosis: a comprehensive literature review","volume":"9","author":"Davis","year":"2024","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0036","doi-asserted-by":"crossref","first-page":"165","DOI":"10.14309\/ajg.0000000000000501","article-title":"ACG clinical guideline: small intestinal bacterial overgrowth","volume":"115","author":"Pimentel","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0037","first-page":"610","article-title":"Evaluation of dietary fiber intake in Belgian children with cystic fibrosis: is there a link with gastrointestinal complaints?","volume":"35","author":"Proesmans","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2026.03.023_bib0038","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00535-017-1371-9","article-title":"Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth","volume":"53","author":"Su","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0039","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1440-1754.1998.00159.x","article-title":"Bowel dysfunction in cystic fibrosis: importance of breath testing","volume":"34","author":"Lewindon","year":"1998","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.jcf.2026.03.023_bib0040","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2020.06.090","article-title":"AGA clinical practice update on small intestinal bacterial overgrowth: expert review","volume":"159","author":"Quigley","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcf.2026.03.023_bib0041","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3389\/fmicb.2018.02147","article-title":"Diet, microbiota and gut-lung connection","volume":"9","author":"Anand","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0042","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12866-021-02305-z","article-title":"Infants with cystic fibrosis have altered fecal functional capacities with potential clinical and metabolic consequences","volume":"21","author":"Eng","year":"2021","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0043","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jcf.2023.09.010","article-title":"Changes in fecal lipidome after treatment with ivacaftor without changes in microbiome or bile acids","volume":"23","author":"Bass","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0044","doi-asserted-by":"crossref","DOI":"10.1038\/srep22493","article-title":"Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis","volume":"6","author":"Manor","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2026.03.023_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55028-7","article-title":"Gut microbiota in children with cystic Fibrosis: a taxonomic and functional dysbiosis","volume":"9","author":"Coffey","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2026.03.023_bib0046","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41598-024-77864-y","article-title":"Key features and guidelines for the application of microbial alpha diversity metrics","volume":"15","author":"Cassol","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2026.03.023_bib0047","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s10620-022-07812-1","article-title":"Cystic fibrosis-related gut dysbiosis: a systematic review","volume":"68","author":"Caley","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jcf.2026.03.023_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1342833","article-title":"Gut dysbiosis in patients with chronic pain: a systematic review and meta-analysis","volume":"15","author":"Goudman","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0049","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1093\/rheumatology\/keaa847","article-title":"An association between chronic widespread pain and the gut microbiome","volume":"60","author":"Freidin","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jcf.2026.03.023_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2025.1545997","article-title":"The brain-gut axis and chronic pain: mechanisms and therapeutic opportunities","volume":"19","author":"Ho","year":"2025","journal-title":"Front Neurosci"},{"key":"10.1016\/j.jcf.2026.03.023_bib0051","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/gast.2002.32392","article-title":"Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?","volume":"122","author":"Whitehead","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcf.2026.03.023_bib0052","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.berh.2011.02.005","article-title":"Central pain mechanisms in chronic pain states\u2013maybe it is all in their head","volume":"25","author":"Phillips","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0053","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11030809","article-title":"Association among disorders of gut-brain interaction (DGBI) and fibromyalgia: a prospective study","volume":"11","author":"Settembre","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2026.03.023_bib0054","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71021","article-title":"The Dutch gastrointestinal symptom tracker for people with cystic fibrosis: associations with anxiety, depression, and health-related quality of life","volume":"60","author":"Verkleij","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0055","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40271-019-00361-2","article-title":"Validity and reliability of a novel multimodal questionnaire for the assessment of abdominal symptoms in people with cystic fibrosis (CFAbd-Score)","volume":"12","author":"Jaudszus","year":"2019","journal-title":"Patient"},{"key":"10.1016\/j.jcf.2026.03.023_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpdig.2025.100203","article-title":"CF tummy tracker: a cystic fibrosis-specific patient reported outcome measure for daily gastrointestinal symptom burden","author":"Calthorpe","year":"2025","journal-title":"Mayo Clin Proc Digit Health"},{"key":"10.1016\/j.jcf.2026.03.023_bib0057","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jcf.2020.12.021","article-title":"Designing the GALAXY study: partnering with the cystic fibrosis community to optimize assessment of gastrointestinal symptoms","volume":"20","author":"Freeman","year":"2021","journal-title":"J Cys Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.07.013","article-title":"Estimating minimal clinically important difference (MCID) for gastrointestinal symptoms in cystic fibrosis","author":"Lee","year":"2024","journal-title":"J Cys Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0060","article-title":"How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey","volume":"7","author":"Smith","year":"2020","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.jcf.2026.03.023_bib0061","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jcf.2019.11.007","article-title":"Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy","volume":"19","author":"Gifford","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0062","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/ajg.2016.538","article-title":"Distinct abnormalities of small bowel and regional colonic volumes in subtypes of irritable bowel syndrome revealed by MRI","volume":"112","author":"Lam","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0063","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S2468-1253(23)00398-9","article-title":"Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"9","author":"Di Lorenzo","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.03.023_bib99","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11938-024-00460-6","article-title":"Chronic Constipation in Persons with Cystic Fibrosis: Management and Treatment Options","volume":"22","author":"Sultan","year":"2024","journal-title":"Current Treat Opt Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2026.03.023_bib100","first-page":"S81","article-title":"Constipation and DIOS: Diagnosis, differential diagnosis, and management","volume":"59","author":"Saikumar","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0064","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/bph.15323","article-title":"Inhibition of Na(+) \/H(+) exchanger isoform 3 improves gut fluidity and alkalinity in cystic fibrosis transmembrane conductance regulator-deficient and F508del mutant mice","volume":"178","author":"Tan","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179993","article-title":"The NHE3 inhibitor tenapanor prevents intestinal obstructions in CFTR-deleted mice","volume":"23","author":"Tan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2026.03.023_bib0066","doi-asserted-by":"crossref","first-page":"L324","DOI":"10.1152\/ajplung.00277.2012","article-title":"Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelia","volume":"304","author":"Schiffhauer","year":"2013","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0067","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2009.05.037","article-title":"Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator","volume":"137","author":"Bijvelds","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcf.2026.03.023_bib0068","doi-asserted-by":"crossref","first-page":"G868","DOI":"10.1152\/ajpgi.00261.2017","article-title":"Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium\/hydrogen exchanger 3","volume":"315","author":"McHugh","year":"2018","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0069","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1345\/aph.1Q219","article-title":"Lubiprostone for constipation in adults with cystic fibrosis: a pilot study","volume":"45","author":"O'Brien","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jcf.2026.03.023_bib0070","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27431","article-title":"Linaclotide use for the treatment of constipation and gastrointestinal symptoms in people with cystic fibrosis","volume":"60","author":"Kormelink","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0071","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0328015","article-title":"Effect of cystic fibrosis transmembrane conductance regulator modulators and dedicated cystic fibrosis gastrointestinal clinic visits on the incidence of distal intestinal obstructive syndrome in persons with cystic fibrosis","volume":"20","author":"Wongjarupong","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2026.03.023_bib0072","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/ajg.2017.46","article-title":"Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus","volume":"112","author":"Rezaie","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2026.03.023_bib0073","first-page":"S70","article-title":"The gastrointestinal microbiome, small bowel bacterial overgrowth, and microbiome modulators in cystic fibrosis","volume":"59","author":"Green","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0074","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41586-023-05989-7","article-title":"Profiling the human intestinal environment under physiological conditions","volume":"617","author":"Shalon","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jcf.2026.03.023_bib0075","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14965","article-title":"Evaluation of a novel smart capsule bacterial detection system device for diagnosis of small intestinal bacterial overgrowth","volume":"37","author":"Lee","year":"2025","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.jcf.2026.03.023_bib0076","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/j.1572-0241.2008.02030.x","article-title":"Small intestinal bacterial overgrowth recurrence after antibiotic therapy","volume":"103","author":"Lauritano","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0077","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1080\/17474124.2021.2005579","article-title":"Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0078","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00535-018-1509-4","article-title":"The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin","volume":"54","author":"Furnari","year":"2019","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0079","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.amjms.2016.05.012","article-title":"Lubiprostone accelerates intestinal transit and alleviates small intestinal bacterial overgrowth in patients with chronic constipation","volume":"352","author":"Sarosiek","year":"2016","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jcf.2026.03.023_bib101","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jand.2019.01.003","article-title":"The Relative Contribution of Food Groups to Macronutrient Intake in Children with Cystic Fibrosis: A European Multicenter Assessment","volume":"119","author":"Calvo-Lerma","year":"2019","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.jcf.2026.03.023_bib102","first-page":"14","article-title":"Utilization of the Healthy Eating Index in Cystic Fibrosis","author":"Bass","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.jcf.2026.03.023_bib105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/adc.76.1.35","article-title":"Dietary fibre and the occurrence of gut symptoms in cystic fibrosis","volume":"76","author":"Gavin","year":"1997","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jcf.2026.03.023_bib103","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1756283X11436241","article-title":"Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals?","volume":"5","author":"Barrett","year":"2012","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0080","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/apt.70420","article-title":"Clinical trial: rifaximin versus low FODMAP diet in irritable bowel syndrome","volume":"63","author":"Chuah","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jcf.2026.03.023_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2025.03.002","article-title":"Effect, tolerability, and safety of exclusive palatable elemental diet in patients with intestinal microbial overgrowth","volume":"23","author":"Rezaie","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.03.023_bib0082","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jcf.2014.02.007","article-title":"Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study","volume":"13","author":"del Campo","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0083","first-page":"61","article-title":"Effectiveness of probiotics, prebiotics, and symbiotic supplementation in cystic fibrosis patients: a systematic review and meta-analysis of clinical trials","author":"Cruz Mosquera","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jcf.2026.03.023_bib0084","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/jhn.12991","article-title":"Probiotic use in adults with cystic fibrosis is common and influenced by gastrointestinal health needs: a cross-sectional survey study","volume":"35","author":"Anderson","year":"2022","journal-title":"J Hum Nutr Diet"},{"key":"10.1016\/j.jcf.2026.03.023_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2024.101278","volume":"38","author":"Sivapiromrat","year":"2024","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.jcf.2026.03.023_bib0086","article-title":"Prebiotics for people with cystic fibrosis","volume":"9","author":"Williams","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2026.03.023_bib0087","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jcf.2025.05.006","article-title":"Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor\/tezacaftor\/ivacaftor: findings from the promise study","volume":"24","author":"Duong","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0089","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jcf.2024.05.002","article-title":"Impact of extended Elexacaftor\/Tezacaftor\/Ivacaftor therapy on the gut microbiome in cystic fibrosis","volume":"23","author":"Marsh","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0090","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01935-23","article-title":"Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor","volume":"15","author":"Reasoner","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.jcf.2026.03.023_bib0091","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2026.03.023_bib0092","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01175-23","article-title":"Tezacaftor\/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome","volume":"11","author":"Marsh","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jcf.2026.03.023_bib0093","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jcf.2020.12.002","article-title":"Changes in fecal microbiota with CFTR modulator therapy: a pilot study","volume":"20","author":"Pope","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.023_bib0094","article-title":"Distinct gastrointestinal symptom phenotypes in adults with Cystic Fibrosis are linked to complications and medication use","volume":"2026","author":"Holaman","year":"2026","journal-title":"MedRxiv"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:45:26Z","timestamp":1781883926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326000895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1569199326000895"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.03.023","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maldigestion, dysbiosis, inflammation and dysmotility: a toxic tetrad in the CF gut","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}